CJC/IPA Blend 5/5mg

No. They are two structurally unrelated peptides studied at different receptors. CJC-1295 is a growth hormone releasing hormone analogue examined at the GHRH receptor. Ipamorelin is a pentapeptide, C38H49N9O5 at 711.9 g/mol, CAS 170851-70-4, examined at the growth hormone secretagogue receptor. Both are catalogued in the growth hormone axis research group, which is why Oasis Labs lists them as a combined blend in addition to selling each on its own.

The blend contains two separate compounds in one vial: Modified GRF 1-29, also known as CJC-1295 without DAC, at C152H252N44O42 and 3367.9 g/mol, CAS 863288-34-0; together with Ipamorelin at C38H49N9O5 and 711.9 g/mol, CAS 170851-70-4. It is supplied as a 5mg / 5mg presentation. The lot-specific Certificate of Analysis documents the identity and purity of both components.

The two components are examined at different receptors in published preclinical literature. The GRF 1-29 sequence has been studied as an agonist at the growth hormone releasing hormone receptor, and Ipamorelin as a selective agonist at the growth hormone secretagogue receptor. Reported work in both cases concerns receptor binding and downstream signalling in in vitro and animal models. Oasis Labs supplies this material strictly as a research reagent. No human or veterinary use is described, supported or intended.

SKU CJC-IPA-5-5MG. Supplied as a 5mg / 5mg vial of lyophilized powder at 99%+ documented purity. Component identities: Modified GRF 1-29, C152H252N44O42, 3367.9 g/mol, CAS 863288-34-0; and Ipamorelin, C38H49N9O5, 711.9 g/mol, CAS 170851-70-4. Identity, purity and net content are documented per lot on the Certificate of Analysis.

Oasis Labs supplies the CJC-1295 / Ipamorelin blend direct to researchers from the USA, with fulfilment handled in Las Vegas, Nevada. Current pricing and bulk options are shown on the product page. Every lot is third-party tested and the Certificate of Analysis is published on the site and can be read in full before ordering. The COA is available at myoasislabs.com/coa/cjc-ipa-blend-5-5mg/ and the full testing methodology is documented at myoasislabs.com/coa-process/.

No. This product is sold FOR RESEARCH USE ONLY and is not for human or veterinary use, including medical, therapeutic or diagnostic applications. It is intended exclusively for in vitro laboratory research conducted by qualified professionals. It is not a drug, food, cosmetic, dietary supplement or medical device, and nothing on this page describes or recommends administration to humans or animals.

Yes. Every lot of CJC/IPA Blend 5/5mg from Oasis Labs Peptides is analyzed by independent, U.S.-based third-party laboratories using HPLC and mass spectrometry to confirm identity and purity against the label. Each batch is backed by a lot-specific Certificate of Analysis you can pull on demand. CJC/IPA Blend 5/5mg is supplied strictly for laboratory research use only.

Oasis Labs Peptides publishes a lot-level Certificate of Analysis for every batch of CJC/IPA Blend 5/5mg. You can look it up by product and lot in the COA library, where identity and purity are confirmed by independent U.S. third-party labs and matched to the production lot supplied. CJC/IPA Blend 5/5mg is supplied strictly for laboratory research use only.

Researchers choose Oasis Labs Peptides for CJC/IPA Blend 5/5mg because every batch is released against a documented purity specification, confirmed by HPLC and mass spectrometry, tested by domestic third-party labs rather than overseas certificates, and paired to a traceable production lot. It is offered strictly for research purposes only.